|
1
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells - perspectives on current status and future directions:
AACR Workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kurrey NK, Jalgaonkar SP, Joglekar AV,
Ghanate AD, Chaskar PD, Doiphode RY and Bapat SA: Snail and slug
mediate radioresistance and chemoresistance by antagonizing
p53-mediated apoptosis and acquiring a stem-like phenotype in
ovarian cancer cells. Stem Cells. 27:2059–2068. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee SH, Lee SJ, Chung JY, Jung YS, Choi
SY, Hwang SH, Choi D, Ha NC and Park BJ: p53, secreted by
K-Ras-Snail pathway, is endocytosed by K-Ras-mutated cells;
implication of target-specific drug delivery and early diagnostic
marker. Oncogene. 28:2005–2014. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cross DA, Alessi DR, Cohen P, Andjelkovich
M and Hemmings BA: Inhibition of glycogen synthase kinase-3 by
insulin mediated by protein kinase B. Nature. 378:785–789. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou BP, Deng J, Xia W, Xu J, Li YM,
Gunduz M and Hung MC: Dual regulation of Snail by
GSK-3beta-mediated phosphorylation in control of
epithelial-mesenchymal transition. Nat Cell Biol. 6:931–940. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Castellano E and Downward J: RAS
interaction with PI3K: More than just another effector pathway.
Genes Cancer. 2:261–274. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang SP, Wang WL, Chang YL, Wu CT, Chao
YC, Kao SH, Yuan A, Lin CW, Yang SC, Chan WK, et al: p53 controls
cancer cell invasion by inducing the MDM2-mediated degradation of
Slug. Nat Cell Biol. 11:694–704. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Y, Ngo VN, Marani M, Yang Y, Wright
G, Staudt LM and Downward J: Critical role for transcriptional
repressor Snail2 in transformation by oncogenic RAS in colorectal
carcinoma cells. Oncogene. 29:4658–4670. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hsu DS, Lan HY, Huang CH, Tai SK, Chang
SY, Tsai TL, Chang CC, Tzeng CH, Wu KJ, Kao JY, et al: Regulation
of excision repair cross-complementation group 1 by Snail
contributes to cisplatin resistance in head and neck cancer. Clin
Cancer Res. 16:4561–4571. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gan Y, Shi C, Inge L, Hibner M, Balducci J
and Huang Y: Differential roles of ERK and Akt pathways in
regulation of EGFR-mediated signaling and motility in prostate
cancer cells. Oncogene. 29:4947–4958. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang TH, Tsai MF, Su KY, Wu SG, Huang CP,
Yu SL, Yu YL, Lan CC, Yang CH, Lin SB, et al: Slug confers
resistance to the epidermal growth factor receptor tyrosine kinase
inhibitor. Am J Respir Crit Care Med. 183:1071–1079. 2011.
View Article : Google Scholar
|
|
14
|
Horiguchi K, Shirakihara T, Nakano A,
Imamura T, Miyazono K and Saitoh M: Role of Ras signaling in the
induction of snail by transforming growth factor-beta. J Biol Chem.
284:245–253. 2009. View Article : Google Scholar
|
|
15
|
Chang CJ, Chao CH, Xia W, Yang JY, Xiong
Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH, et al: p53 regulates
epithelial-mesenchymal transition and stem cell properties through
modulating miRNAs. Nat Cell Biol. 13:317–323. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei
Y, Abbruzzese JL, Hortobagyi GN and Hung MC: Epidermal growth
factor receptor cooperates with signal transducer and activator of
transcription 3 to induce epithelial-mesenchymal transition in
cancer cells via up-regulation of TWIST gene expression. Cancer
Res. 67:9066–9076. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Van Meter ME, Díaz-Flores E, Archard JA,
Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K and Braun BS:
K-RasG12D expression induces hyperproliferation and
aberrant signaling in primary hematopoietic stem/progenitor cells.
Blood. 109:3945–3952. 2007. View Article : Google Scholar
|
|
18
|
Lin T, Chao C, Saito S, Mazur SJ, Murphy
ME, Appella E and Xu Y: p53 induces differentiation of mouse
embryonic stem cells by suppressing Nanog expression. Nat Cell
Biol. 7:165–171. 2005. View
Article : Google Scholar
|
|
19
|
Aguirre A, Rubio ME and Gallo V: Notch and
EGFR pathway interaction regulates neural stem cell number and
self-renewal. Nature. 467:323–327. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Niedernhofer LJ, Essers J, Weeda G,
Beverloo B, de Wit J, Muijtjens M, Odijk H, Hoeijmakers JH and
Kanaar R: The structure-specific endonuclease Ercc1-Xpf is required
for targeted gene replacement in embryonic stem cells. EMBO J.
20:6540–6549. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Riely GJ, Marks J and Pao W: KRAS
mutations in non-small cell lung cancer. Proc Am Thorac Soc.
6:201–205. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mogi A and Kuwano H: TP53 mutations in
nonsmall cell lung cancer. J Biomed Biotechnol. 2011:5839292011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Olaussen KA, Dunant A, Fouret P, Brambilla
E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH,
et al; IALT Bio Investigators. DNA repair by ERCC1 in
non-small-cell lung cancer and cisplatin-based adjuvant
chemotherapy. N Engl J Med. 355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mok TS: Personalized medicine in lung
cancer: What we need to know. Nat Rev Clin Oncol. 8:661–668. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tellez CS, Juri DE, Do K, Bernauer AM,
Thomas CL, Damiani LA, Tessema M, Leng S and Belinsky SA: EMT and
stem cell-like properties associated with miR-205 and miR-200
epigenetic silencing are early manifestations during
carcinogen-induced transformation of human lung epithelial cells.
Cancer Res. 71:3087–3097. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chiou SH, Wang ML, Chou YT, Chen CJ, Hong
CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS, et al:
Coexpression of Oct4 and Nanog enhances malignancy in lung
adenocarcinoma by inducing cancer stem cell-like properties and
epithelial-mesenchymal transdifferentiation. Cancer Res.
70:10433–10444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gandhi J, Zhang J, Xie Y, Soh J,
Shigematsu H, Zhang W, Yamamoto H, Peyton M, Girard L, Lockwood WW,
et al: Alterations in genes of the EGFR signaling pathway and their
relationship to EGFR tyrosine kinase inhibitor sensitivity in lung
cancer cell lines. PLoS One. 4:e45762009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Takezawa K, Okamoto I, Yonesaka K,
Hatashita E, Yamada Y, Fukuoka M and Nakagawa K: Sorafenib inhibits
non-small cell lung cancer cell growth by targeting B-RAF in KRAS
wild-type cells and C-RAF in KRAS mutant cells. Cancer Res.
69:6515–6521. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou J, Oliveira P, Li X, Chen Z and
Bepler G: Modulation of the ribonucleotide reductase-antimetabolite
drug interaction in cancer cell lines. J Nucleic Acids.
2010:5970982010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mitsudomi T, Steinberg SM, Nau MM, Carbone
D, D'Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD,
et al: p53 gene mutations in non-small-cell lung cancer cell lines
and their correlation with the presence of ras mutations and
clinical features. Oncogene. 7:171–180. 1992.PubMed/NCBI
|
|
32
|
O'Connor PM, Jackman J, Bae I, Myers TG,
Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN,
et al: Characterization of the p53 tumor suppressor pathway in cell
lines of the National Cancer Institute anticancer drug screen and
correlations with the growth-inhibitory potency of 123 anticancer
agents. Cancer Res. 57:4285–4300. 1997.PubMed/NCBI
|
|
33
|
You L, Yang CT and Jablons DM: ONYX-015
works synergistically with chemotherapy in lung cancer cell lines
and primary cultures freshly made from lung cancer patients. Cancer
Res. 60:1009–1013. 2000.PubMed/NCBI
|
|
34
|
McDermott U, Ames RY, Iafrate AJ,
Maheswaran S, Stubbs H, Greninger P, McCutcheon K, Milano R, Tam A,
Lee DY, et al: Ligand-dependent platelet-derived growth factor
receptor (PDGFR)-alpha activation sensitizes rare lung cancer and
sarcoma cells to PDGFR kinase inhibitors. Cancer Res. 69:3937–3946.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jensen DE, Proctor M, Marquis ST, Gardner
HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y,
et al: BAP1: A novel ubiquitin hydrolase which binds to the BRCA1
RING finger and enhances BRCA1-mediated cell growth suppression.
Oncogene. 16:1097–1112. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamadori T, Ishii Y, Homma S, Morishima Y,
Kurishima K, Itoh K, Yamamoto M, Minami Y, Noguchi M and Hizawa N:
Molecular mechanisms for the regulation of Nrf2-mediated cell
proliferation in non-small-cell lung cancers. Oncogene.
31:4768–4777. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Basu A and Krishnamurthy S: Cellular
responses to cisplatin-induced DNA damage. J Nucleic Acids.
2010:2013.672010. View Article : Google Scholar
|
|
38
|
Kuo LJ and Yang LX: Gamma-H2AX - a novel
biomarker for DNA double-strand breaks. In Vivo. 22:305–309.
2008.PubMed/NCBI
|
|
39
|
Yang J, Xu ZP, Huang Y, Hamrick HE,
Duerksen-Hughes PJ and Yu YN: ATM and ATR: Sensing DNA damage.
World J Gastroenterol. 10:155–160. 2004.PubMed/NCBI
|
|
40
|
Vega S, Morales AV, Ocaña OH, Valdés F,
Fabregat I and Nieto MA: Snail blocks the cell cycle and confers
resistance to cell death. Genes Dev. 18:1131–1143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fan S, Smith ML, Rivet DJ II, Duba D, Zhan
Q, Kohn KW, Fornace AJ Jr and O'Connor PM: Disruption of p53
function sensitizes breast cancer MCF-7 cells to cisplatin and
pentoxifylline. Cancer Res. 55:1649–1654. 1995.PubMed/NCBI
|
|
42
|
Lodish H, Berk A, Zipursky SL, Matsudaira
P, Baltimore D and Darnell J: Molecular Cell Biology. Molecular
Cell Biology. W. H. Freeman; New York: 2000
|
|
43
|
Rodrigues CO, Nerlick ST, White EL,
Cleveland JL and King ML: A Myc-Slug (Snail2)/Twist regulatory
circuit directs vascular development. Development. 135:1903–1911.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Seger R and Krebs EG: The MAPK signaling
cascade. FASEB J. 9:726–735. 1995.PubMed/NCBI
|
|
45
|
Liu J, Uygur B, Zhang Z, Shao L, Romero D,
Vary C, Ding Q and Wu WS: Slug inhibits proliferation of human
prostate cancer cells via downregulation of cyclin D1 expression.
Prostate. 70:1768–1777. 2010.PubMed/NCBI
|
|
46
|
Cheon MG, Kim W, Choi M and Kim JE: AK-1,
a specific SIRT2 inhibitor, induces cell cycle arrest by
downregulating Snail in HCT116 human colon carcinoma cells. Cancer
Lett. 356:637–645. 2015. View Article : Google Scholar
|
|
47
|
Takahashi E, Funato N, Higashihori N, Hata
Y, Gridley T and Nakamura M: Snail regulates p21WAF/CIP1
expression in cooperation with E2A and Twist. Biochem Biophys Res
Commun. 325:1136–1144. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Barrallo-Gimeno A and Nieto MA: The Snail
genes as inducers of cell movement and survival: Implications in
development and cancer. Development. 132:3151–3161. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kondo M, Wagers AJ, Manz MG, Prohaska SS,
Scherer DC, Beilhack GF, Shizuru JA and Weissman IL: Biology of
hematopoietic stem cells and progenitors: Implications for clinical
application. Annu Rev Immunol. 21:759–806. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Vignot S, Frampton GM, Soria JC, Yelensky
R, Commo F, Brambilla C, Palmer G, Moro-Sibilot D, Ross JS, Cronin
MT, et al: Next-generation sequencing reveals high concordance of
recurrent somatic alterations between primary tumor and metastases
from patients with non-small-cell lung cancer. J Clin Oncol.
31:2167–2172. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Vakiani E, Janakiraman M, Shen R, Sinha R,
Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, et al:
Comparative genomic analysis of primary versus metastatic
colorectal carcinomas. J Clin Oncol. 30:2956–2962. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gupta PB, Chaffer CL and Weinberg RA:
Cancer stem cells: Mirage or reality? Nat Med. 15:1010–1012. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Curtis SJ, Sinkevicius KW, Li D, Lau AN,
Roach RR, Zamponi R, Woolfenden AE, Kirsch DG, Wong KK and Kim CF:
Primary tumor genotype is an important determinant in
identification of lung cancer propagating cells. Cell Stem Cell.
7:127–133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sutherland KD, Song JY, Kwon MC, Proost N,
Zevenhoven J and Berns A: Multiple cells-of-origin of mutant
K-Ras-induced mouse lung adenocarcinoma. Proc Natl Acad Sci USA.
111:4952–4957. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kreso A and Dick JE: Evolution of the
cancer stem cell model. Cell Stem Cell. 14:275–291. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Shields MA, Khan MW, Grippo PJ and Munshi
HG: Concurrent Snail expression and Kras mutation promote
pancreatic fibrosis. Cancer Res. 72:13362012. View Article : Google Scholar
|
